From Forgotten Pathogen to Target for New Vaccines: What Clinicians Need to Know about Respiratory Syncytial Virus Infection in Older Adults

Matteo Boattini; André Almeida; Sara Comini; Gabriele Bianco; Rossana Cavallo; Cristina Costa

doi:10.3390/v16040531

From Forgotten Pathogen to Target for New Vaccines: What Clinicians Need to Know about Respiratory Syncytial Virus Infection in Older Adults

Matteo Boattini, André Almeida, Sara Comini, Gabriele Bianco, Rossana Cavallo, Cristina Costa

NOVA Medical School|Faculdade de Ciências Médicas (NMS|FCM)

Research output: Contribution to journal › Review article › peer-review

4 Citations (Scopus)

35 Downloads (Pure)

Abstract

Respiratory syncytial virus (RSV) is increasingly recognized as being implicated in acute illness in older adults, with a significant weight in hospitalizations for respiratory illness and death. By means of a best-evidence review, this paper aims to investigate whether RSV can be considered a forgotten pathogen in older patients, looking at trends in the literature volume and exploring possible epidemiological and clinical features underlying the focus given to it. We then present an assessment of its disease burden and present and future strategies for its reduction, particularly in light of the recent availability of new vaccines.

Original language	English
Article number	531
Journal	Viruses
Volume	16
Issue number	4
DOIs	https://doi.org/10.3390/v16040531
Publication status	Published - Apr 2024

Keywords

elderly
older adults
pneumonia
respiratory syncytial virus
RSV
vaccine

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.3390/v16040531

viruses-16-00531Final published version, 1.17 MBLicence: CC BY

Cite this

@article{45716c58e5d648a290e0007f14eef63d,

title = "From Forgotten Pathogen to Target for New Vaccines: What Clinicians Need to Know about Respiratory Syncytial Virus Infection in Older Adults",

abstract = "Respiratory syncytial virus (RSV) is increasingly recognized as being implicated in acute illness in older adults, with a significant weight in hospitalizations for respiratory illness and death. By means of a best-evidence review, this paper aims to investigate whether RSV can be considered a forgotten pathogen in older patients, looking at trends in the literature volume and exploring possible epidemiological and clinical features underlying the focus given to it. We then present an assessment of its disease burden and present and future strategies for its reduction, particularly in light of the recent availability of new vaccines.",

keywords = "elderly, older adults, pneumonia, respiratory syncytial virus, RSV, vaccine",

author = "Matteo Boattini and Andr{\'e} Almeida and Sara Comini and Gabriele Bianco and Rossana Cavallo and Cristina Costa",

note = "Funding Information: This study was supported by EU funding within the MUR PNRR Extended Partnership initiative on Emerging Infectious Diseases (Project no. PE00000007, INF-ACT). Publisher Copyright: {\textcopyright} 2024 by the authors.",

year = "2024",

month = apr,

doi = "10.3390/v16040531",

language = "English",

volume = "16",

journal = "Viruses",

issn = "1999-4915",

publisher = "MDPI - Multidisciplinary Digital Publishing Institute",

number = "4",

}

TY - JOUR

T1 - From Forgotten Pathogen to Target for New Vaccines

T2 - What Clinicians Need to Know about Respiratory Syncytial Virus Infection in Older Adults

AU - Boattini, Matteo

AU - Almeida, André

AU - Comini, Sara

AU - Bianco, Gabriele

AU - Cavallo, Rossana

AU - Costa, Cristina

N1 - Funding Information: This study was supported by EU funding within the MUR PNRR Extended Partnership initiative on Emerging Infectious Diseases (Project no. PE00000007, INF-ACT). Publisher Copyright: © 2024 by the authors.

PY - 2024/4

Y1 - 2024/4

N2 - Respiratory syncytial virus (RSV) is increasingly recognized as being implicated in acute illness in older adults, with a significant weight in hospitalizations for respiratory illness and death. By means of a best-evidence review, this paper aims to investigate whether RSV can be considered a forgotten pathogen in older patients, looking at trends in the literature volume and exploring possible epidemiological and clinical features underlying the focus given to it. We then present an assessment of its disease burden and present and future strategies for its reduction, particularly in light of the recent availability of new vaccines.

AB - Respiratory syncytial virus (RSV) is increasingly recognized as being implicated in acute illness in older adults, with a significant weight in hospitalizations for respiratory illness and death. By means of a best-evidence review, this paper aims to investigate whether RSV can be considered a forgotten pathogen in older patients, looking at trends in the literature volume and exploring possible epidemiological and clinical features underlying the focus given to it. We then present an assessment of its disease burden and present and future strategies for its reduction, particularly in light of the recent availability of new vaccines.

KW - elderly

KW - older adults

KW - pneumonia

KW - respiratory syncytial virus

KW - RSV

KW - vaccine

UR - http://www.scopus.com/inward/record.url?scp=85191350324&partnerID=8YFLogxK

U2 - 10.3390/v16040531

DO - 10.3390/v16040531

M3 - Review article

C2 - 38675874

AN - SCOPUS:85191350324

SN - 1999-4915

VL - 16

JO - Viruses

JF - Viruses

IS - 4

M1 - 531

ER -

From Forgotten Pathogen to Target for New Vaccines: What Clinicians Need to Know about Respiratory Syncytial Virus Infection in Older Adults

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this